ArticleNature communications2024
Cryo-EM structures of Candida albicans Cdr1 reveal azole-substrate recognition and inhibitor blocking mechanisms.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Disulfiram reverses fluconazole-resistance mediated by Cdr1 in Candida albicans and interferes with biofilm formation.Applied microbiology and biotechnology · 2026Article
- Cryo-EM structures of Cdr1 reveal snapshots of substrate transport and diverse inhibitor recognition.Science advances · 2026Article
- New Acylglucoses fromPlants (Basel, Switzerland) · 2026Article
- Unraveling competitive protein interactions: A critical step toward improved production and therapeutics.Journal of advanced research · 2026Review
- Generation of antifungals to combat drug resistance using language models and diffusion models.Journal of advanced research · 2026Article
- Bridging the "Valley of Death" in Antifungal Therapy: Next-Generation Biomimetic and Exosome-Inspired Nanocarriers for Invasive Candidiasis.Journal of fungi (Basel, Switzerland) · 2026Review
- Agricultural fungicides shape soil and sediment reservoirs of multidrug-resistant fungi.Nature communications · 2026Article
- Vacuolar iron transporters mediate resistance to triadimefon in plant pathogenic fungi.Nature communications · 2026Article
- Article
- Flavonoids as a Potential Antifungal Alternative AgainstJournal of fungi (Basel, Switzerland) · 2026Article
- Genetic variation and mutational determinants of azole resistance in Candida albicans strains of oropharyngeal colonization in HIV patients and bloodstream infections.Journal of biomedical science · 2026Article
- Review
- Capsaicin inhibits cariogenicJournal of oral microbiology · 2026Article
- Fungi between threat and promise: global perspectives on health and innovation.Frontiers in microbiology · 2026Review
- Impact of milbemycin oxime on fluconazole resistance inJAC-antimicrobial resistance · 2025Article
- Comparative functional analysis of a new CDR1-like ABC transporter gene in multidrug resistance and virulence between Magnaporthe oryzae and Trichophyton mentagrophytes.Cell communication and signaling : CCS · 2025Article
- Cdr1 in focus: a personal reflection on multidrug transporter research.FEMS yeast research · 2025Article
- Functional analysis of Candida albicans Cdr1 through homologous and heterologous expression studies.FEMS yeast research · 2025Review
- Use of gain-of-function suppressor screening to elucidateFrontiers in microbiology · 2025Article
- Azole Combinations and Multi-Targeting Drugs That Synergistically InhibitJournal of fungi (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Candida albicans, Cdr1 pumps azole drugs out of the cells to reduce intracellular accumulation at detrimental concentrations, leading to azole-drug resistance. Milbemycin oxime, a veterinary anti-parasitic drug, strongly and specifically inhibits Cdr1. However, how Cdr1 recognizes and exports azole drugs, and how milbemycin oxime inhibits Cdr1 remain unclear. Here, we report three cryo-EM structures of Cdr1 in distinct states: the apo state (Cdr1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.